No Picture
News

Neurelis Announces Four Poster Presentations For The Joint Meeting Of The International Child Neurology Association And Child Neurology Society

– Data continue to support the unique clinical attributes for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and … […]

No Picture
News

Amplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific Conferences

– Oral presentation of positive phase 2 results from a study of fosmanogepix in candidemia to be presented at IDWeek 2020- First preclinical and clinical data on anti-BKV monoclonal antibody MAU868 to be presented at Kidney Week 2020

SAN DIEGO, Oc… […]

No Picture
News

Gigadocking(TM) in Orion(TM) Molecular Design Platform Rapidly Identifies Novel Chemical Entities for GPCR Targets

OpenEye Scientific Helps Beacon Discovery Increase Speed and Improve Activity in Virtual Screening

SANTA FE, N.M., & SAN DIEGO, Oct. 15, 2020 /PRNewswire/ — OpenEye Scientific and Beacon Discovery today announced the rapid identification of two … […]

No Picture
News

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

LA JOLLA, Calif., Oct. 15, 2020 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced … […]

No Picture
News

Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi

Proceeds Used to Repay Debt Principal with Oxford Finance

LA JOLLA, Calif., Oct. 13, 2020 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS) (the “Company” or “Regulus”), a biopharmaceutical company focused on the discovery and development of i… […]

No Picture
News

Ionis’ inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis

– Data from the first clinical study of IONIS-ENAC-2.5 Rx to be presented at North American Cystic Fibrosis Conference

CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, a… […]

No Picture
News

Exonbio announces the launch of SARS-CoV-2 Neutralizing Anti-spike monoclonal antibody for development of Antigen Assays and Therapeutics for COVID-19

SAN DIEGO, Oct. 7, 2020 /PRNewswire/ — Exonbio, a leading recombinant antibody CRO company now launches the SARS-CoV-2 Spike recombinant monoclonal antibodies for the global IVD and research communities in support of efforts to combat the pandemic…. […]

No Picture
News

Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments(TM), an Online Community Platform and Charitable Initiative to Support, Inspire and Connect People During the Pandemic

– Monumental Moments Encourages People to Share How They are Caring for Their Mental Health during These Unprecedented and Challenging Times on Social Media with Hashtag #MonumentalMoments- Me2/Orchestra, World’s Only Known Classical Music Organization… […]

No Picture
News

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results

Conference Call and Webcast Scheduled for Monday, November 9

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Mon… […]